Abstract: Despite the finding that rtL180M and rtM204V/I were higher among ART-experienced individuals, the overall prevalence of DRMs (48.0% versus 36.4%) showed no significance difference among antiretroviral therapy (ART) status.
Abstract: Lamivudine selected DRMs, that is, rtL180M (29.3%) and rtM204V/I (29.3%) and rtV173L (15.5%) were more prevalent in HBV-HIV-coinfected individuals but absent in HBV-monoinfected individuals.
Abstract: RESULTS: In 34 out of 161 study subjects (21.1%) HBV drug resistance mutations (DRM
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Discussion: In our study, twenty (95.2%) of the 21 patients had at least one mutation that may confer clinical resistance to both telbivudine (rtM204V/I) and 3TC (rt180M + rtM204V/I, rtV173L + rtL180M + rtM204V/I, and rtL80I + rtM204I).
Discussion: The 3TC mutations rtL80I, rtV173L, PMID: 27006281
2016
Infection, genetics and evolution
Abstract: In addition, two patients harboring drug resistance mutations rtL80V+rtM204I and rtL180M+rtM204V were found.
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
PMID: 26136470
2016
The Journal of infectious diseases
Abstract: The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%).
Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultradeep pyrosequencing.
Result: Although all 12 patients experienced viral breakthrough during the treatment with LAM, low rates of drug resistance-associated mutations were observed at week 0 prior to the treatment, with the exception of patient D, who exhibited a rate of 94.03 for M204I, and patient G, who exhibited a rate of 97.59 for A181V.
Result: Furthermore, the increased mutation rate of rt180 or rt80 was accompanied by the occurrence of the high mutation rate of M204I during the virological breakthrough.
Result: Notably, the mutation rate of rt
Discussion: The present study also revealed that the NUC-associated mutations existed in treatment naive patients, for example, patient D, who exhibited a high mutation rate of M204I at the baseline.
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.
Abstract: The mutation M204V/I conferring resistance to 3TC was more common in HBV/A (47.4%) than in HBV/E isolates (0%) (P = .04).
Introduction: Regarding HBV mutations, the use of 3TC alone has been shown to be strongly associated with consistently high HBV viremia due to the rapid emergence of HBV mutants carrying the M204I/V mutation conferring resistance to 3TC/FTC.
Method: Using th
Discussion: Importantly, we identified in our survey three natural M204V/I mutations in 3TC-naive patients, as already described in other settings.
Discussion: Third, the M204V/I RAM were more common in HBV/A strains.
Discussion: When considering HBV/A genotypes only, we observed a high (~50%) prevalence of M204V/I and L180M mutations.
Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.
Result: At baseline, this patient displayed rtM204I/V (3.5%), rtL180 M (2.1%), and rtS202G (3.4%) substitutions, and the resistance and nonresistance mutations frequencies were significantly different (P = 0.011).
Result: Eight patients harbored rtM204I/V substitutions of at least 1% (ranging from 1% to 3.6%); 2 of these patients also presented rtL180 M substitutions (2.3% and 2.4%) and rtS202G substitutions (3.2% and 3.5%), whereas the other 6 harbored a low frequency of rtS202G substitut
Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone.
PMID: 26831605
2016
Saudi journal of gastroenterology
Discussion: Newly developed HBV rtM204I and rtP237H mutants were detected, and the pre-existing HBV rtA181V mutant disappeared completely through rescue therapy.
Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China.
PMID: 26876337
2016
The Brazilian journal of infectious diseases
Abstract: Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including rtM204I/V (n=6), rtN236T (n=5), rtM250V (n=2), rtL180M (n=2), rtT184G (n=1), rtM207I (n=1), rtS202I (n=1), rtM204V/I & rtL180M (n=5), and rtM204I &
HBV mutation literature information.
PMID: 
2017
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT